GLP-1 RA and Basal Insulin: Individualizing Therapy for Clinical Practice

Endocrinology
Curriculum:
GLP-1 RA and Basal Insulin Combinations: New Options for Treatment Intensification
Credits:
1.5 AMA PRA Category 1 Credits
Launch Date:
11-Jul-17
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Primary Care Providers, Nurse Practitioners, Physician Assistants

Relevant Terms:

Type 2 Diabetes; Insulin; Glp-1 Receptor Agonists; Combination Therapy

Mark E. Molitch, MD

Mark E. Molitch, MD
Martha Leland Sherwin Professor of Endocrinology
Division of Endocrinology, Metabolism and Molecular Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL

Dr. Molitch graduated from the University of Pennsylvania School of Medicine in 1969. He did his housestaff training at the Hospital of the University of Pennsylvania and his Endocrine Fellowship at UCLA-Harbor General Hospital in Los Angeles. His first faculty position was at Tufts University Medical School in Boston and he moved to Northwestern University in Chicago in 1984. At present, he is the Martha Leland Sherwin Professor of Endocrinology at Northwestern in the Division of Endocrinology, Metabolism and Molecular Medicine.
 
Dr. Molitch has been active in clinical research in diabetes and other areas of endocrinology and served as the Principal Investigator for the Northwestern Center of the Diabetes Control and Complications Trial. In the DCCT, he was chair of the Complications Committee and was a member of the Planning Committee. At present, he remains Principal Investigator of the Northwestern Center for several NIH-sponsored studies, including the DCCT follow-up study called "Epidemiology of Diabetes and Its Complications" (EDIC), the Diabetes Prevention Program Observational Study (DPPOS), and the Prevention of Early Renal Loss (PERL) study. He was also Co-Principal Investigator of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) study.
 
Dr. Molitch has been active in the American Diabetes Association (ADA). He chaired the Professional Practice Committee that wrote the 2002 ADA "Standards of Medical Care for Patients with Diabetes Mellitus," chaired the working group that wrote the ADA Position Statement "Diabetic Nephropathy," and served as chair of the ADA's Provider Recognition Program. He also chaired the Technical Expert Review Panel of the National Diabetes Quality Improvement Alliance. Dr. Molitch is on the working group that wrote the KDOQI Guideline for the treatment of diabetic kidney disease prepared by the National Kidney Foundation and its recent revision. 
 
In addition to editing eight books and journal volumes, Dr. Molitch has authored or coauthored more than 400 original papers, review articles, book chapters, case reports and other publications. In 1997, Dr. Molitch was named "Outstanding Physician Educator in the Field of Diabetes" by the American Diabetes Association. He was awarded the "Distinguished Educator Award" of The Endocrine Society for 2013. He was elected to the Council of The Endocrine Society from 2007 to 2010 and completed a 3 year term as the Chair of The Endocrine Society's Clinical Endocrinology Update in 2012. He was also the President of The Pituitary Society from 2012-2013. 

‚ÄčLyle D. Mitzner, MD

Lyle D. Mitzner, MD
Assistant Professor of Medicine, Harvard Medical School
Attending Physician in Endocrinology, Beth Israel Deaconess Medical Center
Staff Physician, Joslin Diabetes Center
Boston, MA

Dr. Mitzner is a Clinician Educator at the Joslin Clinic and Assistant Professor of Medicine at Harvard Medical School. He is also an endocrinology consulting physician at Beth Israel Deaconess Medical Center and New England Baptist Hospital. His major interests include clinical diabetes and endocrinology. His inpatient management of diabetics is an area that he worked in at Joslin's local teaching hospital developing treatment algorithms. He has served as a medical consultant.
 
 
1. Implement strategies that reduce barriers to treatment intensification in patients on OADs and/or insulin
2. Outline the advantages of a pathophysiologic approach to the management of dysglycemia in T2DM
3. Describe the glucose lowering effects of short- and long-acting GLP-1 receptor agonists
4. Incorporate fixed-ratio combination GLP-1 RA and basal insulin products in the treatment of patients with T2DM

LAUNCH DATE/EXPIRATION DATE
This activity was launched on July 11, 2017 and will expire on July 25, 2018.
 
TARGET AUDIENCE
This activity has been designed to meet the educational needs of primary care providers, NPs, PAs and other health care professionals involved in the care of patients with Type 2 diabetes.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
HOW TO CLAIM CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.5 AMA PRA Category 1 Credits™. Statement of credit will be available to print from your user history page.
 
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
 
Name of Faculty Reported Financial Relationship
Lyle Mitzner, MD
Dr. Mitnzer has served on an Advisory Board for Conversa Health.
Mark Molitch, MD Dr. Molitch has served on an Advisory Board for Janssen, Novo Nordisk, and he has performed contracted research for Bayer, Novo Nordisk, Novartis, Calibra Bioceuticals, Prolor Biotech, and Chiasma. Dr. Molitch has received funds for consulting from Merck, Pfizer, Novartis, and Chiasma.
 
OTHER CONTRIBUTORS Non-faculty contributors and others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any ACCME defined commercial interest.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
SUPPORTER ACKNOWLEDGEMENT
This activity is supported by an educational grant from Sanofi US.       
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above